| ［1］ |
王丽玮, 罗玲玲, 崔盘根, 等. 肠道菌群与银屑病关系的研究进展［J］. 中华皮肤科杂志, 2019,52（5）:357⁃360. doi: 10.3760/cma.j.issn.0412⁃4030.2019.05.018.
|
| ［2］ |
Rea D, Coppola G, Palma G, et al. Microbiota effects on cancer: from risks to therapies［J］. Oncotarget, 2018,9（25）:17915⁃17927. doi: 10.18632/oncotarget.24681.
|
| ［3］ |
Clos⁃Garcia M, Garcia K, Alonso C, et al. Integrative analysis of fecal metagenomics and metabolomics in colorectal cancer［J］. Cancers （Basel）, 2020,12（5）:1142. doi: 10.3390/cancers1205 1142.
|
| ［4］ |
Fine RL, Mubiru DL, Kriegel MA. Friend or foe? Lactobacillus in the context of autoimmune disease［J］. Adv Immunol, 2020,146:29⁃56. doi: 10.1016/bs.ai.2020.02.002.
|
| ［5］ |
Chandra S, Alam MT, Dey J, et al. Healthy gut, healthy brain: the gut microbiome in neurodegenerative disorders［J］. Curr Top Med Chem, 2020,20（13）:1142⁃1153. doi: 10.2174/1568026 620666200413091101.
|
| ［6］ |
Hermes G, Reijnders D, Kootte RS, et al. Individual and cohort⁃specific gut microbiota patterns associated with tissue⁃specific insulin sensitivity in overweight and obese males［J］. Sci Rep, 2020,10（1）:7523. doi: 10.1038/s41598⁃020⁃64574⁃4.
|
| ［7］ |
Limeta A, Ji B, Levin M, et al. Meta-analysis of the gut microbiota in predicting response to cancer immunotherapy in metastatic melanoma［J］. JCI Insight, 2020,5（23）:e140940. doi: 10.1172/jci.insight.140940.
|
| ［8］ |
McQuade JL, Daniel CR, Helmink BA, et al. Modulating the microbiome to improve therapeutic response in cancer［J］. Lancet Oncol, 2019,20（2）:e77⁃e91. doi: 10.1016/S1470⁃2045（18）30952⁃5.
|
| ［9］ |
Tözün N, Vardareli E. Gut microbiome and gastrointestinal cancer: les liaisons dangereuses［J］. J Clin Gastroenterol, 2016,50（Suppl 2）:S191⁃S196. doi: 10.1097/MCG.0000000000000714.
|
| ［10］ |
Sivan A, Corrales L, Hubert N, et al. Commensal Bifidobacterium promotes antitumor immunity and facilitates anti⁃PD⁃L1 efficacy［J］. Science, 2015,350（6264）:1084⁃1089. doi: 10.1126/science.aac4255.
|
| ［11］ |
Li Y, Tinoco R, Elmén L, et al. Gut microbiota dependent anti⁃tumor immunity restricts melanoma growth in Rnf5⁃/⁃ mice［J］. Nat Commun, 2019,10（1）:1492. doi: 10.1038/s41467⁃019⁃09525⁃y.
|
| ［12］ |
Sethi V, Kurtom S, Tarique M, et al. Gut microbiota promotes tumor growth in mice by modulating immune response［J］. Gastroenterology, 2018,155（1）:33⁃37.e6. doi: 10.1053/j.gastro. 2018.04.001.
|
| ［13］ |
Routy B, Le Chatelier E, Derosa L, et al. Gut microbiome influences efficacy of PD⁃1⁃based immunotherapy against epithelial tumors［J］. Science, 2018,359（6371）:91⁃97. doi: 10. 1126/science.aan3706.
|
| ［14］ |
Botticelli A, Zizzari I, Mazzuca F, et al. Cross⁃talk between microbiota and immune fitness to steer and control response to anti PD⁃1/PDL⁃1 treatment［J］. Oncotarget, 2017,8（5）:8890⁃8899. doi: 10.18632/oncotarget.12985.
|
| ［15］ |
Hamid O, Robert C, Daud A, et al. Five⁃year survival outcomes for patients with advanced melanoma treated with pembrolizumab in KEYNOTE⁃001［J］. Ann Oncol, 2019,30（4）:582⁃588. doi: 10.1093/annonc/mdz011.
|
| ［16］ |
Dai WF, Beca JM, Croxford R, et al. Real⁃world comparative effectiveness of second⁃line ipilimumab for metastatic melanoma: a population⁃based cohort study in Ontario, Canada［J］. BMC Cancer, 2020,20（1）:304. doi: 10.1186/s12885⁃020⁃06798⁃1.
|
| ［17］ |
Peters BA, Wilson M, Moran U, et al. Relating the gut metagenome and metatranscriptome to immunotherapy responses in melanoma patients［J］. Genome Med, 2019,11（1）:61. doi: 10. 1186/s13073⁃019⁃0672⁃4.
|
| ［18］ |
Frankel AE, Coughlin LA, Kim J, et al. Metagenomic shotgun sequencing and unbiased metabolomic profiling identify specific human gut microbiota and metabolites associated with immune checkpoint therapy efficacy in melanoma patients［J］. Neoplasia, 2017,19（10）:848⁃855. doi: 10.1016/j.neo.2017.08.004.
|
| ［19］ |
Matson V, Fessler J, Bao R, et al. The commensal microbiome is associated with anti⁃PD⁃1 efficacy in metastatic melanoma patients［J］. Science, 2018,359（6371）:104⁃108. doi: 10.1126/science.aao3290.
|
| ［20］ |
Gopalakrishnan V, Spencer CN, Nezi L, et al. Gut microbiome modulates response to anti⁃PD⁃1 immunotherapy in melanoma patients［J］. Science, 2018,359（6371）:97⁃103. doi: 10.1126/science.aan4236.
|
| ［21］ |
Nguyen TL, Vieira⁃Silva S, Liston A, et al. How informative is the mouse for human gut microbiota research?［J］. Dis Model Mech, 2015,8（1）:1⁃16. doi: 10.1242/dmm.017400.
|
| ［22］ |
Humphries A, Daud A. The gut microbiota and immune checkpoint inhibitors［J］. Hum Vaccin Immunother, 2018,14（9）:2178⁃2182. doi: 10.1080/21645515.2018.1442970.
|
| ［23］ |
Bhatt AP, Redinbo MR, Bultman SJ. The role of the microbiome in cancer development and therapy［J］. CA Cancer J Clin, 2017,67（4）:326⁃344. doi: 10.3322/caac.21398.
|
| ［24］ |
Buchbinder EI, Desai A. CTLA⁃4 and PD⁃1 pathways: similarities, differences, and implications of their inhibition［J］. Am J Clin Oncol, 2016,39（1）:98⁃106. doi: 10.1097/COC.0000 000000000239.
|
| ［25］ |
Vétizou M, Pitt JM, Daillère R, et al. Anticancer immunotherapy by CTLA⁃4 blockade relies on the gut microbiota［J］. Science, 2015,350（6264）:1079⁃1084. doi: 10.1126/science.aad1329.
|
| ［26］ |
Chaput N, Lepage P, Coutzac C, et al. Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab［J］. Ann Oncol, 2017,28（6）:1368⁃1379. doi: 10.1093/annonc/mdx108.
|
| ［27］ |
Coutzac C, Jouniaux JM, Paci A, et al. Systemic short chain fatty acids limit antitumor effect of CTLA⁃4 blockade in hosts with cancer［J］. Nat Commun, 2020,11（1）:2168. doi: 10.1038/s41467⁃020⁃16079⁃x.
|
| ［28］ |
Derosa L, Hellmann MD, Spaziano M, et al. Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non⁃small⁃cell lung cancer［J］. Ann Oncol, 2018,29（6）:1437⁃1444. doi: 10.1093/annonc/mdy103.
|
| ［29］ |
Xu C, Ruan B, Jiang Y, et al. Antibiotics⁃induced gut microbiota dysbiosis promotes tumor initiation via affecting APC⁃Th1 development in mice［J］. Biochem Biophys Res Commun, 2017,488（2）:418⁃424. doi: 10.1016/j.bbrc.2017.05.071.
|
| ［30］ |
Jenkins SV, Robeson MS 2nd, Griffin RJ, et al. Gastrointestinal tract dysbiosis enhances distal tumor progression through suppression of leukocyte trafficking［J］. Cancer Res, 2019,79（23）:5999⁃6009. doi: 10.1158/0008⁃5472.CAN⁃18⁃4108.
|
| ［31］ |
Elkrief A, El Raichani L, Richard C, et al. Antibiotics are associated with decreased progression⁃free survival of advanced melanoma patients treated with immune checkpoint inhibitors［J］. Oncoimmunology, 2019,8（4）:e1568812. doi: 10.1080/21624 02X.2019.1568812.
|
| ［32］ |
Pinato DJ, Howlett S, Ottaviani D, et al. Association of prior antibiotic treatment with survival and response to immune checkpoint inhibitor therapy in patients with cancer［J］. JAMA Oncol, 2019,5（12）:1774⁃1778. doi: 10.1001/jamaoncol.2019.2785.
|
| ［33］ |
Seidel DV, Azcárate⁃Peril MA, Chapkin RS, et al. Shaping functional gut microbiota using dietary bioactives to reduce colon cancer risk［J］. Semin Cancer Biol, 2017,46:191⁃204. doi: 10.1016/j.semcancer.2017.06.009.
|
| ［34］ |
Shokryazdan P, Jahromi MF, Liang JB, et al. In vitro assessment of bioactivities of Lactobacillus strains as potential probiotics for humans and chickens［J］. J Food Sci, 2017,82（11）:2734⁃2745. doi: 10.1111/1750⁃3841.13921.
|
| ［35］ |
Valcheva R, Koleva P, Martínez I, et al. Inulin⁃type fructans improve active ulcerative colitis associated with microbiota changes and increased short⁃chain fatty acids levels［J］. Gut Microbes, 2019,10（3）:334⁃357. doi: 10.1080/19490976.2018. 1526583.
|
| ［36］ |
Sanders ME, Merenstein DJ, Reid G, et al. Probiotics and prebiotics in intestinal health and disease: from biology to the clinic［J］. Nat Rev Gastroenterol Hepatol, 2019,16（10）:605⁃616. doi: 10.1038/s41575⁃019⁃0173⁃3.
|
| ［37］ |
Dong M, Meng Z, Kuerban K, et al. Diosgenin promotes antitumor immunity and PD⁃1 antibody efficacy against melanoma by regulating intestinal microbiota［J］. Cell Death Dis, 2018,9（10）:1039. doi: 10.1038/s41419⁃018⁃1099⁃3.
|
| ［38］ |
Li Y, Elmén L, Segota I, et al. Prebiotic⁃induced anti⁃tumor immunity attenuates tumor growth［J］. Cell Rep, 2020,30（6）:1753⁃1766.e6. doi: 10.1016/j.celrep.2020.01.035.
|
| ［39］ |
Dubin K, Callahan MK, Ren B, et al. Intestinal microbiome analyses identify melanoma patients at risk for checkpoint⁃blockade⁃induced colitis［J］. Nat Commun, 2016,7:10391. doi: 10.1038/ncomms10391.
|
| ［40］ |
樊逸夫, 白晓敏, 杜娟. 肠道菌群对肿瘤影响的研究进展［J］. 癌症进展, 2019,17（15）:1741⁃1744. doi: 10.11877/j.issn.1672⁃1535.2019.17.15.02.
|
| ［41］ |
Zmora N, Zilberman⁃Schapira G, Suez J, et al. Personalized gut mucosal colonization resistance to empiric probiotics is associated with unique host and microbiome features［J］. Cell, 2018,174（6）:1388⁃1405.e21. doi: 10.1016/j.cell.2018.08.041.
|
